JAN vs. AGE, ADXN, ELAB, ERNA, MTEM, GHSI, BNTC, IMNN, EDSA, and MNPR
Should you be buying JanOne stock or one of its competitors? The main competitors of JanOne include AgeX Therapeutics (AGE), Addex Therapeutics (ADXN), Elevai Labs (ELAB), Eterna Therapeutics (ERNA), Molecular Templates (MTEM), Guardion Health Sciences (GHSI), Benitec Biopharma (BNTC), Imunon (IMNN), Edesa Biotech (EDSA), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical preparations" industry.
AgeX Therapeutics (NYSE:AGE) and JanOne (NASDAQ:JAN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
AgeX Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, JanOne has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.
AgeX Therapeutics received 49 more outperform votes than JanOne when rated by MarketBeat users.
JanOne has higher revenue and earnings than AgeX Therapeutics.
JanOne has a net margin of 0.00% compared to JanOne's net margin of -10,424.65%. AgeX Therapeutics' return on equity of 1.55% beat JanOne's return on equity.
In the previous week, AgeX Therapeutics had 1 more articles in the media than JanOne. MarketBeat recorded 3 mentions for AgeX Therapeutics and 2 mentions for JanOne. AgeX Therapeutics' average media sentiment score of 0.51 beat JanOne's score of 0.00 indicating that JanOne is being referred to more favorably in the news media.
12.5% of AgeX Therapeutics shares are held by institutional investors. Comparatively, 6.3% of JanOne shares are held by institutional investors. 6.5% of AgeX Therapeutics shares are held by insiders. Comparatively, 3.0% of JanOne shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
JanOne beats AgeX Therapeutics on 7 of the 11 factors compared between the two stocks.
Get JanOne News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools